Olivier Elemento

@ElementoLab

Director, Englander Institute for Precision Medicine & Associate Director, Institute for Computational Biomedicine

New York city
Vrijeme pridruživanja: siječanj 2012.

Tweetovi

Blokirali ste korisnika/cu @ElementoLab

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ElementoLab

  1. proslijedio/la je Tweet
    prije 24 sata

    Wow: Google's "Meena" chatbot was trained on a full TPUv3 pod (2048 TPU cores) for **30 full days** - That's more than $1,400,000 of compute time to train this chatbot model. (! 100+ petaflops of sustained compute !)

    Poništi
  2. proslijedio/la je Tweet
    prije 12 sati

    This use of technology & data science provides a basis for rational policy intervention and measurement of effect. Nice work!

    Poništi
  3. proslijedio/la je Tweet
    2. velj

    Data from our US SDOH paper is live with interactive exploration at . Zoom into your area of interest! It's the first iteration, thnx for patience; data to be released soon. Thnx community 4 yr support!

    Poništi
  4. proslijedio/la je Tweet

    I profiled two startups trying to develop blood tests to screen for cancer. They’re taking very different approaches but both teams are optimistic:

    Poništi
  5. proslijedio/la je Tweet
    1. velj

    It was an honor closing out ’s celebration at the Town Hall. Establishing mentoring as an institutional priority is important, and the Academy was a great first step. I encourage mentoring at all levels as part of our culture.

    Poništi
  6. proslijedio/la je Tweet

    Interesting article in the Cornell Chronicle () "Cornell Tech women in tech program goes national," . Related: The AI Health Hackathon begins one week from today!! Learn more:

    Poništi
  7. proslijedio/la je Tweet

    Member Claire Henchcliffe, M.D., will present "Network to Conduct Multi-Center Trials, Trial Innovation Network," during the Grand Rounds celebration of new CTSC Research Systems. Feb. 18, 3-4 PM, Uris Aud., 1300 York Ave.

    Poništi
  8. 31. sij
    Poništi
  9. 31. sij

    Great to see Dr Hahn continuing to endorse Real World Data for use in trial design, conduct and regulatory decision-making. Interesting initiatives in that space include FDA-Sentinel and NIH-ACT

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    First paper in the now posted on so if you ever were curious about the neuro-anatomical localization of the family of proteins, this one is for you.

    Poništi
  11. proslijedio/la je Tweet
    31. sij
    Poništi
  12. proslijedio/la je Tweet
    31. sij

    . has appointed Atefeh Riazi as its new chief information officer, effective February 3.

    Poništi
  13. proslijedio/la je Tweet

    The list of pharma-health tech partnerships that have unraveled recently is getting long: 🔹Sanofi-Onduo 🔹Novartis-Pear 🔹Otsuka-Proteus 🔹Roche-Syapse

    Poništi
  14. 30. sij

    Great meeting. Very diverse perspectives on role and potential of AI in clinical trials

    Poništi
  15. proslijedio/la je Tweet

    Check out our latest research paper on visualizing patient-reported outcomes published today in , funded by . From my lab at , co-first authors , and coauthors report that...

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet

    I say this often, but it’s worth repeating: it really is a special time for cancer research and cancer progress. We’re seeing more and more evidence of that progress, including today’s report from as reported by of

    Poništi
  17. proslijedio/la je Tweet
    30. sij

    Want to work at the leading-edge of diabetes and data science at one of the hottest companies in Precision Medicine? My team at Tempus is hiring.

    Poništi
  18. 30. sij
    Poništi
  19. 30. sij

    Interesting - Eli Lilly dropping support for IDO1, TIM-3 and TGFB programs

    Poništi
  20. proslijedio/la je Tweet
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·